PTO/SB/08b (04-07)
Approved for use through 9/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are require

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

to respond to a conection or miormation unless it displays a valid OMB control number				
Confirmation Number	3160			
Application Number	10/560,482			
Filing Date	December 12, 2005			
First Named Inventor	Janssens, F.E.			
Group Art Unit	4161			
Examiner Name	Bong-Sook Baek			
Attorney Docket Number	PR42077fPCTUS			

	$\overline{}$	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's nitials*	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		TATTERSALL, F.D. et al, "Enantioselective Inhibition of Apomorphine-Induced Emesis in the Ferret by the Neurokinin Receptor Antagonist CP-99,994". Neuropharmacology, 1994, pages 259-260, vol. 33, no. 2.	
		BOUNTRA, C. et al., "Anti-Emetic Profile of a Non-Peptide Neurokinin NK Receptor Antagonist, CP-99,994, in Ferrets. European Journal of Pharmacology, (249) 1993, pages R3-R4.	
		C.J. GARDNER, et al., "GR205171: A Novel Antagonist with High Affinity for the Tachykinin NK Receptor, and Potent Broad-Spectrum Anti-Emetic Activity", Regulatory Peptides, 1996, pages 45-53, vol. 65.	

Examiner Signature	/Bong-Sook Baek/	Date Considered	02/17/2009	

*EXAMINER: Initial if reference considered, whether or not claiston is in conformance with MFEP 080. Draw line through claim or into in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique claim of essipation number (optional): Applicant is to place a check mark here i English language Translation is attached.

This collection of information is required by 37 CFR 13 and 19.8. The information required to obtain or retain a benefit by the public which is to fife (and by the USPT0 or process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection of entire to the confidence of the complete indication in the USPT0. The mass while will be of the complete indication to the USPT0 or the will valve depending onto the end vividual completes implication to the USPT0. The mass what yet operating upon the end vividual completes in the USPT0 or the confidence in the USPT0 or the USPT0 or the confidence in the USPT0 or the USPT0 or the confidence in the USPT0 or the USPT0 o

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.